Mirtazapine Discontinuation: Difficulty and Management
Yes, mirtazapine can be difficult to discontinue and requires gradual tapering rather than abrupt cessation to avoid a well-documented discontinuation syndrome.
Discontinuation Syndrome Profile
The FDA drug label explicitly warns about discontinuation syndrome with mirtazapine 1. Adverse reactions upon discontinuation (particularly when abrupt) include:
- Dizziness and sensory disturbances (paresthesia, electric shock sensations)
- Gastrointestinal symptoms (nausea, vomiting)
- Neuropsychiatric effects (agitation, anxiety, confusion, tremor, abnormal dreams)
- Physical symptoms (fatigue, headache, sweating)
These symptoms can be clinically significant and warrant gradual dose reduction rather than abrupt cessation 1.
Clinical Evidence of Withdrawal Difficulty
The discontinuation syndrome can occur even at low doses and after relatively short treatment durations. A case report documented severe withdrawal symptoms in a patient taking only 15 mg/day for appetite stimulation—symptoms appeared within 48 hours of stopping and included anxiousness, nausea, tremor, loss of appetite, and 8-pound weight loss 2. Symptoms persisted for 14 days until mirtazapine was restarted, after which they resolved immediately.
More dramatically, another case described recurrent panic attacks occurring every 1-2 hours for 5 days after abrupt discontinuation of 30 mg/day taken for just 10 weeks 3. The attacks included palpitations, dyspnea, chest pain, dizziness, nausea, and fear of dying—symptoms that only resolved completely after reintroducing mirtazapine.
Comparison to Other Antidepressants
In a large randomized trial of 478 primary care patients discontinuing various antidepressants (citalopram, fluoxetine, sertraline, or mirtazapine), those who stopped their medication had significantly higher relapse rates (56% vs 39%) and more withdrawal symptoms than those who continued 4. While this study didn't isolate mirtazapine specifically, it demonstrates that discontinuation of this class of medications carries real risks.
Recommended Tapering Approach
The FDA mandates gradual dose reduction rather than abrupt cessation 1. Based on the evidence:
- Never stop mirtazapine abruptly, even at low doses (15 mg) or after short durations (10 weeks)
- Use gradual tapering strategies—recent literature suggests hyperbolic dose reductions or the "10 percent rule" (reducing by 10% of the current dose at each step) 5
- Taper more slowly in the final stages, as withdrawal symptoms often intensify during the last phase of discontinuation 5
- Distinguish withdrawal symptoms from relapse of underlying depression—withdrawal typically occurs within days of dose reduction and includes characteristic sensory disturbances
Critical Clinical Pitfalls
Do not misinterpret withdrawal symptoms as relapse of the underlying condition. Withdrawal symptoms appear rapidly (within 24-48 hours), include distinctive features like electric shock sensations and paresthesias, and respond to medication reinitiation 2, 3. True relapse develops more gradually over weeks.
Provide clear, balanced information to patients before tapering begins to reduce nocebo effects while not minimizing the real possibility of withdrawal symptoms 5. Patients need to understand that withdrawal symptoms are temporary and manageable with proper tapering, but also that they should report severe symptoms promptly.
The evidence is unequivocal: mirtazapine requires careful, gradual discontinuation planning, and patients should be explicitly counseled about this before starting treatment.